Skip to main content
Premium Trial:

Request an Annual Quote

Coriell Establishes West Coast Biobank

NEW YORK (GenomeWeb News) – The Coriell Institute for Medical Research is launching a biobank on the West Coast that will house induced pluripotent stem cell lines, and is using a $10 million grant from the California Institute of Regenerative Medicine to fund the facility.

Coriell, based in Camden, NJ, said on Thursday it is leasing a renovated 1,000-square-foot space at the Buck Institute for Research on Aging in Novato, Calif., to house the biobanking facility.

The institute said its biobank in California will house the world's largest collection of iPS cell lines. Currently, Coriell is host to 83 such lines, but it plans for the satellite biobank in California to expand its capacity to a total of 9,000 lines.

CIRM, an independent state-supported stem cell research funding agency, awarded the $10 million to Coriell in early 2013, alongside a $16 million award to Cellular Dynamics of Madison, Wis., which will create iPS cell lines for 3,000 healthy and diseased donors.

Under the terms of the grant, Coriell will establish the biorepository, which will manage, track, store, and distribute the iPS cell lines that CDI generates, which will represent a wide range of disease areas.

Coriell said it plans to begin accepting and processing samples at the new facility today.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.